Practical application of semaglutide: From evidence-based research to expert decisions

The rapid progress in the development of highly effective weekly incretin-based medications offers increasingly broad opportunities for comprehensive correction of cardiometabolic disorders in patients with type 2 diabetes and/or obesity. This article aims to summarize existing research that confirms the efficacy and safety of one of the most prescribed medications from the class of glucagon-like peptide-1 receptor agonists – weekly semaglutide. In addition to presenting the main results of randomized clinical trials involving semaglutide, special emphasis is placed on experimental and clinical studies related to the drug’s effectiveness in real-world conditions and during specific life periods for patients with type 2 diabetes and/or obesity, such as surgical and endoscopic interventions, bariatric surgery, intermittent fasting, and religious dietary restrictions. Based on this evidence base and their own clinical experience, the interdisciplinary author team proposes practical approaches to adjusting hypoglycemic therapy in patients with type 2 diabetes when combined with semaglutide and switching to other therapies. Practical recommendations for the use of the drug in patients with obesity during the active weight loss phase and the weight maintenance phase are also formulated. Key considerations supporting long-term obesity treatment are presented; however, trial de-escalation therapy schemes are also provided for patients who have successfully modified their lifestyle while achieving target weight outcomes. The reasons and mechanisms behind the most common adverse events associated with semaglutide use, which represent a potential barrier to its utilization, are separately discussed. The most effective measures for their prevention and correction are outlined, which will enable the realization of the therapeutic potential of weekly semaglutide and thus improve patient outcomes in the long-term management of obesity and type 2 diabetes.

1. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 populationrepresentative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027–1050. https://doi.org/10.1016/S0140-6736(23)02750-2.

2. Theilade S, Christensen MB, Vilsbøll T, Knop FK. An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight. Diabetes Obes Metab. 2021;23(Suppl. 1):17–35. https://doi.org/10.1111/dom.14270.

3. Salukhov VV, Yudina AF. Body weight variability as a cardiovascular risk factor. RMJ. 2025;(2):14–20. (In Russ.) https://doi.org/10.32364/2225-2282-2025-2-3.

4. Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463–474. https://doi.org/10.1038/s41569-023-00849-3.

5. Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care. 2024;47(11):1873–1888. https://doi.org/10.2337/dci24-0003.

6. Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020;28(6):1050–1061. https://doi.org/10.1002/oby.22794.

7. Kommu S, Berg RL. Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2024;25(9):e13792. https://doi.org/10.1111/obr.13792.

8. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201–223. https://doi.org/10.1038/s41573-021-00337-8.

9. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–1844. https://doi.org/10.1056/NEJMoa1607141.

10. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–2232. https://doi.org/10.1056/NEJMoa2307563.

11. Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(1):94–105. https://doi.org/10.1111/dom.14551.

12. Nauck MA, Kahle M, Baranov O, Deacon CF, Holst JJ. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagonlike peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(2):200–207. https://doi.org/10.1111/dom.12802.

13. Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7(5):356–367. https://doi.org/10.1016/S2213-8587(19)30066-X.

14. Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021;385(10):896–907. https://doi.org/10.1056/NEJMoa2108269.

15. Salukhov VV, Shustov SB, Petrankov KV. Advantages of combined use of sodium-glucose co-transporter type 2 inhibitors and glucagon-like peptide-1 receptor agonists relatively to cardiovascular and renal outcomes in patients with type 2 diabetes mellitus. Therapy. 2024;10(8):66–76. (In Russ.) https://doi.org/10.18565/therapy.2024.8.66-76.

16. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. Diabetes Care. 2025;48(Suppl. 1):S181–S206. https://doi.org/10.2337/dc25-S009.

17. Дедов ИИ, Шестакова МВ, Майоров АЮ (ред.). Алгоритмы специализированной медицинской помощи больным сахарным диабетом: клинические рекомендации. М.; 2023. 236 с. Режим доступа: https://www.endocrincentr.ru/sites/default/files/specialists/science/clinic-recomendations/2023_alg_sum.pdf.

18. Van Dril E, Allison M, Schumacher C. Deprescribing in type 2 diabetes and cardiovascular disease: Recommendations for safe and effective initiation of glucagon-like peptide-1 receptor agonists in patients on insulin therapy. Am Heart J Plus. 2022;17:100163. https://doi.org/10.1016/j.ahjo.2022.100163.

19. Салухов ВВ. Клинический протокол диагностики и лечения сахарного диабета 2 типа у взрослых. СПб.: МедЛит; 2025. 54 с.

20. Alqifari SF, Alkomi O, Esmail A, Alkhawami K, Yousri S, Muqresh MA et al. Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus. World J Diabetes. 2024;15(3):331–347. https://doi.org/10.4239/wjd.v15.i3.331.

21. Hinnen D. Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes. Diabetes Spectr. 2017;30(3):202–210. https://doi.org/10.2337/ds16-0026.

22. Amaro A, Sugimoto D, Wharton S. Postgrad Med. Efficacy and safety of semaglutide for weight management: evidence from the STEP program. Postgrad Med. 2022;134(1):5–17. https://doi.org/10.1080/00325481.2022.2147326.

23. Seier S, Stamp Larsen K, Pedersen J, Biccler J, Gudbergsen H. Tapering semaglutide to the most effective dose: real-world evidence from a digital weight management programme (TAILGATE). Obes Facts. 2024;17(Suppl. 1):449. Available at: https://conscienhealth.org/wp-content/uploads/2024/05/164Semtapering.pdf.

24. Cengiz A, Wu CC, Lawley SD. Alternative dosing regimens of GLP-1 receptor agonists may reduce costs and maintain weight loss efficacy. Diabetes Obes Metab. 2025;27(4):2251–2258. https://doi.org/10.1111/dom.16229.

25. Salvador R, Moutinho CG, Sousa C, Vinha AF, Carvalho M,Matos C. Semaglutide as a GLP-1 Agonist: A Breakthrough in Obesity Treatment. Pharmaceuticals. 2025;18(3):399. https://doi.org/10.3390/ph18030399.

26. Tzoulis P, Baldeweg SE. Semaglutide for weight loss: unanswered questions. Front Endocrinol. 2024;15:1382814. https://doi.org/10.3389/fendo.2024.1382814.

27. Milder DA, Milder TY, Liang SS, Kam PCA. Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice. Anaesthesia. 2024;79(7):735–747. https://doi.org/10.1111/anae.16306.

28. Sherwin M, Hamburger J, Katz D, DeMaria SJr. Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide. Can J Anaesth. 2023;70(8):1300–1306. https://doi.org/10.1007/s12630-023-02549-5.

29. Silveira SQ, da Silva LM, de Campos Vieira Abib A, de Moura DTH, de Moura EGH, Santos LB et al. Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth. 2023;87:111091. https://doi.org/10.1016/j.jclinane.2023.111091.

30. El-Boghdadly K, Dhesi J, Fabb P, Levy N, Lobo DN, McKechnie A et al. Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement: A consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association. Anaesthesia. 2025;80(4):412–424. https://doi.org/10.1111/anae.16541.

31. Van Zuylen ML, Siegelaar SE, Plummer MP, Deane AM, Hermanides J, Hulst AH. Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration. Br J Anaesth. 2024;132(4):644–648. https://doi.org/10.1016/j.bja.2024.01.001.

32. Yao R, Gala KS, Ghusn W, Abboud DM, Wallace FK, Vargas EJ. Effect of Glucagon-Like Peptide-1 Receptor Agonists on Bowel Preparation for Colonoscopy. Am J Gastroenterol. 2024;119(6):1154–1157. https://doi.org/10.14309/ajg.0000000000002564.

33. Kononova TL, Mikhailova AA, Murasheva AB, Laevskaya MYu, Shlyakhto EV. To help a practicing doctor: what you need to know about the preparation for endoscopic and surgical interventions of patients on therapy with glucagon-like peptide-1 receptor agonists. RMJ. 2025;(2):21–26. (In Russ.) https://doi.org/10.32364/2225-2282-2025-2-4.

34. Sen S, Potnuru PP, Hernandez N, Goehl C, Praestholm C, Sridhar S, Nwokolo OO. Glucagon-like peptide-1 receptor agonist use and residual gastric content before anesthesia. JAMA Surg. 2024;159(6):660–667. https://doi.org/10.1001/jamasurg.2024.0111.

35. Santos LB, Mizubuti GB, da Silva LM, Silveira SQ, Nersessian RSF, Abib ACV et al. Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: A retrospective single center observational study. J Clin Anesth. 2024;99:111668. https://doi.org/10.1016/j.jclinane.2024.111668.

36. Stubbs DJ, Levy N, Dhatariya K. The rationale and the strategies to achieve perioperative glycaemic control. BJA Educ. 2017;17:185–193. https://doi.org/10.1093/bjaed/mkw071.

37. Shiffermiller J, Anderson M, Thompson R. Postoperative Length of Stay in Patients With Stress Hyperglycemia Compared to Patients With Diabetic Hyperglycemia: A Retrospective Cohort Study. J Diabetes Sci Technol. 2024;18(3):556–561. https://doi.org/10.1177/19322968241232695.

38. King WC, Hinerman AS, Belle SH, Wahed AS, Courcoulas AP. Comparison of the Performance of Common Measures of Weight Regain After Bariatric Surgery for Association With Clinical Outcomes. JAMA. 2018;320(15):1560–1569. https://doi.org/10.1001/jama.2018.14433.

39. Redmond IP, Shukla AP, Aronne LJ. Use of Weight Loss Medications in Patients after Bariatric Surgery. Curr Obes Rep. 2021;10(2):81–89. https://doi.org/10.1007/s13679-021-00425-1.

40. Lautenbach A, Wernecke M, Huber TB, Stoll F, Wagner J, Meyhöfer SM et al. The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery-a Retrospective Analysis. Obes Surg. 2022;32(10):3280–3288. https://doi.org/10.1007/s11695-022-06211-9.

41. Nie Y, Zhang Y, Liu B, Meng H. Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Metaanalysis. Obes Surg. 2025;35(3):808–822. https://doi.org/10.1007/s11695-025-07733-8.

42. Çalık Başaran N, Dotan I, Dicker D. Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels. Int J Obes. 2025;49(3):412–417. https://doi.org/10.1038/s41366-024-01461-2.

43. Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429. https://doi.org/10.1172/jci.insight.133429.

44. Llewellyn DC, Logan Ellis H, Aylwin SJB, Oštarijaš E, Green S, Sheridan W et alThe efficacy of GLP-1RAs for the management of postprandial hypoglycemia following bariatric surgery: a systematic review. Obesity. 2023;31(1):20–30. https://doi.org/10.1002/oby.23600.

45. Ilanga M, Heard JC, McClintic J, Lewis D, Martin G, Horn C et al. Use of GLP-1 agonists in high risk patients prior to bariatric surgery: a cohort study. Surg Endosc. 2023;37(12):9509–9513. https://doi.org/10.1007/s00464-023-10387-1

46. Alrasheed T, Alrabiah A, AlBishi LA. Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulinotropic polypeptide and glucagonlike peptide-1 receptor agonists in diabetes mellitus. World J Diabetes. 2024;15(3):331–347. https://doi.org/10.4239/wjd.v15.i3.331.

47. Ibrahim M, Davies MJ, Ahmad E, Annabi FA, Eckel RH, Ba-Essa EM et al. Recommendations for management of diabetes during Ramadan: update 2020, applying the principles of the ADA/EASD consensus. BMJ Open Diabetes Res Care. 2020;8(1):e001248. https://doi.org/10.1136/bmjdrc-2020-001248.

48. Gorgojo-Martínez, JJ, Mezquita-Raya P, Carretero-Gómez J, Castro A, Cebrián-Cuenca A, de Torres-Sánchez A et al. Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. J Clin Med. 2023;12(1):145. https://doi.org/10.3390/jcm12010145.

49. Nakatani Y, Maeda M, Matsumura M, Shimizu R, Banba N, Aso Y et al. Effect of GLP-1 receptor agonist on gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Diabetes Metab. 2017;43(5):430–437. https://doi.org/10.1016/j.diabet.2017.05.009.

50. Brubaker PL, Drucker DJ, Asa SL, Swallow C, Redston M, Greenberg GR. Prolonged gastrointestinal transit in a patient with a glucagon-like peptide (GLP)-1- and -2-producing neuroendocrine tumor. J Clin Endocrinol Metab. 2002;87(7):3078–3083. https://doi.org/10.1210/jcem.87.7.8584.

51. Ueda P, Wintzell V, Melbye M, Eliasson B, Söderling J, Gudbjörnsdottir S et al. Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study. Clin Gastroenterol Hepatol. 2024;22(6):1226–1237.e14. https://doi.org/10.1016/j.cgh.2023.08.034.

52. Jalleh RJ, Marathe CS, Rayner CK, Jones KL, Umapathysivam MM, Wu T et al. Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility. Endocrinology. 2024;166(1):bqae155. https://doi.org/10.1210/endocr/bqae155.

53. Stokes CS, Lammert F. Excess Body Weight and Gallstone Disease. Visc Med. 2021;37(4):254–260. https://doi.org/10.1159/000516418.

54. He L, Wang J, Ping F, Yang N, Huang J, Li Y et al. Association of GlucagonLike Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022;182(5):513–519. https://doi.org/10.1001/jamainternmed.2022.0338.

55. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150–156. https://doi.org/10.1053/j.gastro.2011.02.018.

56. Ayoub M, Chela H, Amin N, Hunter R, Anwar J, Tahan V, Daglilar E. Pancreatitis Risk Associated with GLP-1 Receptor Agonists, Considered as a Single Class, in a Comorbidity-Free Subgroup of Type 2 Diabetes Patients in the United States: A Propensity Score-Matched Analysis. J Clin Med. 2025;14(3):944. https://doi.org/10.3390/jcm14030944.

57. Ayoub M, Faris C, Juranovic T, Chela H, Daglilar E. The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study. Cancers. 2024;16(9):1625. https://doi.org/10.3390/cancers16091625.

58. Winzeler B, da Conceição I, Refardt J, Sailer CO, Dutilh G, Christ-Crain M. Effects of glucagon-like peptide-1 receptor agonists on fluid intake in healthy volunteers. Endocrine. 2020;70(2):292–298. https://doi.org/10.1007/s12020-020-02394-2.

59. McKay NJ, Galante DL, Daniels D. Endogenous glucagon-like peptide-1 reduces drinking behavior and is differentially engaged by water and food intakes in rats. J Neurosci. 2014;34(49):16417–16423. https://doi.org/10.1523/JNEUROSCI.3267-14.2014.

60. Mann JFE, Hansen T, Idorn T, Leiter LA, Marso SP, Rossing P et al. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8(11):880–893. https://doi.org/10.1016/S2213-8587(20)30313-2.

61. Vilsbøll T, Bain SC, Leiter LA, Lingvay I, Matthews D, Simó R et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889–897. https://doi.org/10.1111/dom.13172.

62. Simó R, Hernández C. GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe? Diabetes. 2017;66(6):1453–1460. https://doi.org/10.2337/db16-1364.

63. Jingi AM, Tankeu AT, Ateba NA, Noubiap JJ. Mechanism of worsening diabetic retinopathy with rapid lowering of blood glucose: the synergistic hypothesis. BMC Endocr Disord. 2017;17(1):63. https://doi.org/10.1186/s12902-017-0213-3.

64. Kennedy A, Frank RN. The influence of glucose concentration and hypoxia on VEGF secretion by cultured retinal cells. Curr Eye Res. 2011;36(2):168–177. https://doi.org/10.3109/02713683.2010.521968.

65. Cai CX, Hribar M, Baxter S, Goetz K, Swaminathan SS, Flowers A et al. Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. JAMA Ophthalmol. 2025;143(4):304–314. https://doi.org/10.1001/jamaophthalmol.2024.6555.

66. Bea S, Son H, Bae JH, Cho SW, Shin JY, Cho YM. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study. Diabetes Obes Metab. 2024;26(1):108–117. https://doi.org/10.1111/dom.1529.

67. Bezin J, Gouverneur A, Pénichon M, Mathieu C, Garrel R, Hillaire-Buys D et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care. 2023;46(2):384–390. https://doi.org/10.2337/dc22-1148.

68. Hu W, Song R, Cheng R, Liu C, Guo R, Tang W et al. Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials. Front Endocrinol. 2022;13:927859. https://doi.org/10.3389/fendo.2022.927859.

69. Salukhov VV, Kadin DV. Obesity as an oncological risk factor. Literature review. Meditsinskiy Sovet. 2019;(4):94–102. (In Russ.) https://doi.org/10.21518/2079-701X-2019-4-94-102.

70. Levy S, Attia A, Elshazli RM, Abdelmaksoud A, Tatum D, Aiash H, Toraih EA. Differential Effects of GLP-1 Receptor Agonists on Cancer Risk in Obesity: A Nationwide Analysis of 1.1 Million Patients. Cancers. 2024;17(1):78. https://doi.org/10.3390/cancers17010078.

71. Bartelt K, Joyce B, Gracianette M, Bryer E. No Increased Risk for Thyroid Cancer in Diabetic Patients Prescribed GLP-1 Medications Compared to Those Prescribed Insulin. Epic Research. 2025. Available at: https://epicresearch.org/articles/no-increased-risk-for-thyroid-cancer-indiabetic-patients-prescribed-glp-1-medications-compared-to-thoseprescribed-insulin.